Please assess the completion status of the following clinical trial:

Trial Title: Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. In-hospital cardiac arrest~2. Age ≥ 18 years~3. Received at least one dose of adrenaline during cardiopulmonary resuscitation~Exclusion Criteria:~1. Clearly documented do-not-resuscitate order prior to the cardiac arrest~2. Prior enrollment in the trial~3. Invasive mechanical circulatory support at the time of the cardiac arrest~4. Known or suspected pregnancy at the time of the cardiac arrest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vasopressin and methylprednisolone (Type: EXPERIMENTAL): The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
- Placebo (Type: PLACEBO_COMPARATOR): The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.

Based on this trial design, predict the completion outcome and termination type (if applicable).